Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03556592 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
A Phase 1 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03556592 is a Phase 1 study that has completed, run by LEO Pharma. The registered enrollment target is 40 participants.
The verdict
NCT03556592, a Phase 1 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this trial is to investigate if tralokinumab changes the metabolism of selected CYP substrates in adults with moderate-to-severe AD after: * 14 weeks of treatment with tralokinumab * a single dose of tralokinumab
Interventions
- DRUG Omeprazole
- DRUG Tralokinumab
- DRUG Caffeine
- DRUG Warfarin
- DRUG Metoprolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-08-13 |
| Est. Completion | 2020-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03556592
The ClinicalTrials.gov registry entry for NCT03556592 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Omeprazole is the first listed.
NCT03556592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03556592 about?
NCT03556592 is a clinical study titled "Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4". The purpose of this trial is to investigate if tralokinumab changes the metabolism of selected CYP substrates in adults with moderate-to-severe AD after: * 14 weeks of treatment with tralokinumab * a single dose of tralokinumab
What is the current status of trial NCT03556592?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-08-13. Estimated completion is 2020-06-20.
What interventions are being tested in trial NCT03556592?
The interventions under investigation include: Omeprazole (DRUG), Tralokinumab (DRUG), Caffeine (DRUG), Warfarin (DRUG), Metoprolol (DRUG).
Who is sponsoring clinical trial NCT03556592?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.